Onyx Pharma set to buy Proteolix for up to $851M
Onyx Pharmaceuticals, developer of treatments for liver and late-stage kidney cancer, has moved to acquire Proteolix, provider of a technology that can accelerate the death of cancer cells, for as much as $851 million. Emeryville, Calif.-based Onyx says it wants to incorporate this component, which… Continue Reading
Sans IPO, Bayhill secures $350M in Genentech licensing deal
Months after giving up on its IPO hopes last year — when the market was especially brutal for lifescience companies — Bayhill Therapeutics has landed a licensing deal worth $25 million in upfront cash and equity with Genentech. It could bring in as much as… Continue Reading
Cell Biosciences to launch new tech with $10M
Cell Biosciences announced that it’s just brought in $10 million in a third round of funding to launch its new protein analysis technology used to track cellular pathways. It plans to sell its products to labs and research institutions that are developing medications and chemical… Continue Reading
OncoMed nabs $93M for stem cell programs
OncoMed Pharmaceuticals, a company working to fight cancer using stem cells, added a $93 million tranche to a second round of funding that now totals $154 million. The money will be used to push its lead antibody candidate through phase-two clinical trials.
The Redwood City, Calif…. Continue Reading
ForteBio raises $25M for life science analytical instruments
ForteBio is a Menlo Park, Calif. company that makes instruments for biomolecular analysis in the life sciences. Its instruments can measure proteins, DNA, RNA and other small molecules without the use of labels.
Label-free measurement dispenses with the chemical markers that most techniques use, allowing for… Continue Reading
Proteolix raises $79M for cancer treatment
Proteolix, which is developing drugs to treat cancer by disrupting key cell functions, has raised $79 million in a third round of funding, according to VentureWire. That’s the third largest biotech funding this year.
Nomura Phase4 Ventures, a new investor, led the round, with participation from… Continue Reading
Roundup: Icahn’s board selections, YouTube live streaming plan nixed and more
Here’s the latest action:
Icahn haz board members? – Billionaire investor Carl Icahn is already on Yahoo’s board, but now he needs to fill the two complimentary seats given to him by Yahoo. Edward Meyer and Frank Biondi are the two front runners in AllThingsD’s Kara… Continue Reading
Life sciences briefing: Monday, Feb. 11, 2008
TODAY’S HEADLINES:
PolyRemedy, developer of robotic wound care, takes in $25M (release)
Bacchus Vascular gets $15M for clot-busting device (VentureWire)
Protein-evolution company Modular Genetics gets $1.2M (VentureWire)
PharmatrophiX gets $300K for Alzheimer’s disease prevention drugs (release)
Light Sciences Oncology withdraws IPO (Edgar)
Arizona’s Translational Accelerator launches $20M life-sciences fund (bizjournals.com)
Cornea-reshaper Avedro… Continue Reading
Entrigue Surgical raises $6.3M for ear, nose and throat
Entrigue Surgical, a San Antonio, Tex., medical-devices maker, raised $6.3 million in a first funding round, VentureWire reports (subscription requires), crediting the San Antonio Express-News (no link available). Vertical Group and Prism VentureWorks provided the investment.
According to Entrigue’s bare-bones Web site — which features little… Continue Reading
Bacchus, drug infusion catheter maker, to raise $6.5M more
Bacchus Vascular, a Santa Clara, Calif. maker of a drug infusion catheter, expects to finish raising another $6.5 million round of financing from inside investors, according to VentureWire.
The funding comes from the same investors who poured $7.6 million into the company last year to restart… Continue Reading